Nitroglycerin "dak" (Glyceryl Trinitrate)

Glyceryl trinitrate is converted in the body to nitric oxide, a potent vasodilator. Nitric oxide activates guanylate cyclase, increasing cyclic GMP levels, which relaxes smooth muscle in veins and arteries. This reduces both preload and afterload, decreasing myocardial oxygen consumption and relieving ischemic chest discomfort.

The exact dose of Nitroglycerin “dak” is determined by the prescribing clinician based on the patient’s condition, response, and blood‑pressure profile. Typical sublingual tablets are taken at the onset of chest pain, but the prescriber will specify the appropriate strength, frequency, and any titration schedule.

Safety data for glyceryl trinitrate in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare professional after a thorough risk‑benefit assessment.

To place an order, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Nitroglycerin belongs to the nitrate class, offering rapid relief of angina through vasodilation. Compared with beta‑blockers or calcium‑channel blockers, which primarily reduce heart rate or contractility, nitrates act quickly to lower myocardial oxygen demand. Combination therapy may be used when a single agent does not achieve adequate symptom control.

Store Nitroglycerin “dak” at room temperature, preferably below 25 °C, in its original container to protect it from moisture and light. Keep the product out of reach of children and avoid exposing it to excessive heat or humidity, which could degrade its potency.

Nitroglycerin “dak” is administered sublingually. Place a tablet under the tongue and allow it to dissolve completely without swallowing. The patient should remain seated or lying down during the episode to reduce the risk of dizziness or fainting caused by a sudden drop in blood pressure.

The most serious adverse events include severe hypotension, which can lead to syncope, reflex tachycardia, and, rarely, methemoglobinemia—a condition that impairs oxygen delivery. Patients should be instructed to seek immediate medical attention if they experience fainting, a rapid heartbeat, or signs of cyanosis.

Nitroglycerin “dak” is contraindicated in patients with severe anemia, known hypersensitivity to nitrates, or those currently taking phosphodiesterase‑5 inhibitors (e.g., sildenafil, tadalafil) because of the risk of profound hypotension. It should also be avoided in individuals with uncontrolled low blood pressure until the condition is corrected.